Cerebrovascular Reactivity to Acetazolamide in (Senile) Dementia of Alzheimer’s Type: Relationship to Disease Severity

Stoppe, Gabriela; Schütze, R; Kögler, Andreas; Staedt, J.; Munz, Dieter L.; Emrich, D.; Rüther, Eckart

doi:10.1159/000106925

Cited by 21 publications

(18 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As in the study by Stoppe et al [93], contrasting rates of CBF increase between patients and controls revealed significant CVR CO2 differences in the frontal, parietal and temporal cortices. Baseline flow in these regions was also lower than in controls.…”

Section: Cvrco2 Studies In Adsupporting

confidence: 68%

See 1 more Smart Citation

Cerebrovascular Reactivity to Carbon Dioxide in Alzheimer's Disease

Glodzik

Randall

Rusinek

et al. 2013

JAD

112

View full text Add to dashboard Cite

There is growing evidence that cerebrovascular reactivity to carbon dioxide (CVRCO2) is impaired in Alzheimer’s disease (AD). Preclinical and animal studies suggest chronic hypercontractility in brain vessels in AD. We review (a) preclinical studies of mechanisms for impaired CVRCO2 in AD; (b) clinical studies of cerebrovascular function in subjects with AD dementia, mild cognitive impairment (MCI), and normal cognition. Although results of clinical studies are inconclusive, an increasing number of reports reveal an impairment of vascular reactivity to carbon dioxide in subjects with AD, and possibly also in MCI. Thus, CVRCO2 may be an attractive means to detect an early vascular dysfunction in subjects at risk.

show abstract

Section: Cvrco2 Studies In Adsupporting

confidence: 68%

“…In contrast to these results, Stoppe et al [93] found a significant CVR CO2 impairment in AD. Twelve patients with AD and 9 controls were studied.…”

Section: Cvrco2 Studies In Admentioning

confidence: 65%

Cerebrovascular Reactivity to Carbon Dioxide in Alzheimer's Disease

Glodzik

Randall

Rusinek

et al. 2013

JAD

112

View full text Add to dashboard Cite

show abstract

“…On the other hand, the hypercapnia challenge in SPECT and PET studies give ambiguous results without convincing evidence of decreased cerebrovascular reserve capacity in AD (Yamaguchi et al, 1980; Bonte et al, 1989; Kuwabara et al, 1992; Stoppe et al, 1995; Knapp et al, 1996; Jagust et al, 1997; Oishi et al, 1999; Pavics et al, 1999). However, it must be taken into account that in earlier publications, the diagnostic criteria for AD may differ from nowadays criteria and older devices may not give very accurate results (Glodzik et al, 2013).…”

Section: Transcranial Ultrasound In Admentioning

confidence: 99%

Neurosonological Examination: A Non-Invasive Approach for the Detection of Cerebrovascular Impairment in AD

Urbanová

Tomek

Mikulík

et al. 2014

Front. Behav. Neurosci.

View full text Add to dashboard Cite

There has been a growing interest in vascular impairment associated with Alzheimer's disease (AD). This interest was stimulated by the findings of higher incidence of vascular risk factors in AD. Signs of vascular impairment were investigated notably in the field of imaging methods. Our aim was to explore ultrasonographic studies of extra-and intracranial vessels in patients with AD and mild cognitive impairment (MCI) and define implications for diagnosis, treatment, and prevention of the disease. The most frequently studied parameters with extracranial ultrasound are intima-media thickness in common carotid artery, carotid atherosclerosis, and total cerebral blood flow. The transcranial ultrasound concentrates mostly on flow velocities, pulsatility indices, cerebrovascular reserve capacity, and cerebral microembolization. Studies suggest that there is morphological and functional impairment of cerebral circulation in AD compared to healthy subjects. Ultrasound as a non-invasive method could be potentially useful in identifying individuals in a higher risk of progression of cognitive decline.

show abstract

“…2,3 Most AD cases (60% to 90%) are associated with ischemic vascular disease, and 90% of AD patients exhibit cerebral amyloid angiopathy (CAA), a vascular disease caused by amyloid deposition in the vessels. 1 An association between AD and reduced vascular reactivity, a physiological consequence of CAA, was demonstrated with transcranial Doppler, [4][5][6] functional magnetic resonance imaging (fMRI), 7,8 positron emission tomography (PET), 9 and single-photon emission computed tomography (SPECT) 10 techniques. Neurovascular coupling (NVC), the localized vasodilation that occurs from a specific metabolic demand, is also reduced in AD with visual 11 and verbal fluency 12 challenges.…”

Section: Introductionmentioning

confidence: 99%

Differential pathlength factor informs evoked stimulus response in a mouse model of Alzheimer’s disease

et al. 2015

View full text Add to dashboard Cite

Abstract. Baseline optical properties are typically assumed in calculating the differential pathlength factor (DPF) of mouse brains, a value used in the modified Beer-Lambert law to characterize an evoked stimulus response. We used spatial frequency domain imaging to measure in vivo baseline optical properties in 20-month-old control (n ¼ 8) and triple transgenic APP/PS1/tau (3xTg-AD) (n ¼ 5) mouse brains. Average μ a for control and 3xTg-AD mice was 0.82 AE 0.05 and 0.65 AE 0.05 mm −1 , respectively, at 460 nm; and 0.71 AE 0.04 and 0.55 AE 0.04 mm −1 , respectively, at 530 nm. Average μ 0 s for control and 3xTg-AD mice was 1.5 AE 0.1 and 1.7 AE 0.1 mm −1 , respectively, at 460 nm; and 1.3 AE 0.1 and 1.5 AE 0.1 mm −1 , respectively, at 530 nm. The calculated DPF for control and 3xTg-AD mice was 0.58 AE 0.04 and 0.64 AE 0.04 OD mm, respectively, at 460 nm; and 0.66 AE 0.03 and 0.73 AE 0.05 OD mm, respectively, at 530 nm. In hindpaw stimulation experiments, the hemodynamic increase in brain tissue concentration of oxyhemoglobin was threefold larger and two times longer in the control mice compared to 3xTg-AD mice. Furthermore, the washout of deoxyhemoglobin from increased brain perfusion was seven times larger in controls compared to 3xTg-AD mice (p < 0.05).

show abstract

Cerebrovascular Reactivity to Acetazolamide in (Senile) Dementia of Alzheimer’s Type: Relationship to Disease Severity

Cited by 21 publications

References 55 publications

Cerebrovascular Reactivity to Carbon Dioxide in Alzheimer's Disease

Cerebrovascular Reactivity to Carbon Dioxide in Alzheimer's Disease

Neurosonological Examination: A Non-Invasive Approach for the Detection of Cerebrovascular Impairment in AD

Differential pathlength factor informs evoked stimulus response in a mouse model of Alzheimer’s disease

Contact Info

Product

Resources

About